Loading company…
Nuvig Therapeutics develops therapies for immune disorders and related diseases.
Based in California, US, Nuvig Therapeutics was co-founded by Pamela Conley (CEO) and Greg Coffey. It develops protein and antibody therapies for immune disorders, aiming to treat disease while maintaining normal immune function. In December 2024, it raised USD 161 million in Series B funding co-led by Blue Owl Capital, Norwest Venture Partners, and Sanofi Ventures, with participation from Abrdn, Alexandria Venture Investments, B Capital Group, Global BioAccess Fund, Leaps by Bayer, Lotte Corp., Bristol-Myers Squibb Company, Digitalis Ventures, Mission BioCapital, Novo Holdings, and Platanus Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in